Takeda Says 2nd Circ. Shouldn't Revive Actos Antitrust Row

Takeda urged the Second Circuit on Thursday to affirm the dismissal of antitrust claims over alleged delays in generic competition for the diabetes drug Actos, saying the district court correctly demanded...

Already a subscriber? Click here to view full article